Results 41 to 50 of about 479,258 (314)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Constructing the placebo effect in the placebo wars: What is the way ahead? [PDF]

, 2012
The concept of placebo has had a long history in medicine, and has evolved over time with the introduction of randomized controlled trials for health treatments, the increasing research done around the psychotherapies, the development of complementary ...
Ridge, Damien T., Foot, D.
core  

Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility [PDF]

, 2011
<p>Background: Surgical placebos are controversial. This in-depth study explored the design, acceptability, and feasibility issues relevant to designing a surgical placebo-controlled trial for the evaluation of the clinical and cost effectiveness ...
Campbell, MK, McDonald, AM, Skea, Z.C, Sutherland, AG, ZC Skea, Norrie, J.D, Campbell, M.K., Cuthbertson BH, Bridgman, S., McDonald, A.M, BH Cuthbertson, AM McDonald, McDonald AM, RV Carlson, McDonald, A.M., Skea, Z.C., S Bridgman, Carlson, R V, Entwistle, V.A, Sutherland, A.G, Cuthbertson, B H, JD Norrie, Norrie, J. D., Campbell, M K, Cuthbertson, B. H., Skea, Z. C., Skea, ZC, Carlson, RV, Sutherland AG, null null, MK Campbell, Carlson, R.V., Entwistle, Vikki, McDonald, A M, Norrie, JD, Skea ZC, VA Entwistle, Carlson, R.V, Skea, Z C, AG Sutherland, Entwistle, V A, Carlson RV, Entwistle, V.A., Norrie, J D, Sutherland, A.G., Bridgman, S, Norrie, J.D., Entwistle, V. A., Sutherland, A G, Campbell, M.K, Entwistle VA, McDonald, A. M., KORAL study group, Cuthbertson, B.H., Sutherland, A. G., Cuthbertson, B.H, Campbell MK, Campbell, M. K., Entwistle, VA, Cuthbertson, BH, Bridgman S, Carlson, R. V., Norrie JD   +62 more
core   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

The Role of Expectation and Beliefs on the Effects of Non-Invasive Brain Stimulation

Brain Sciences, 2021
Non-invasive brain stimulation (NIBS) techniques are used in clinical and cognitive neuroscience to induce a mild magnetic or electric field in the brain to modulate behavior and cortical activation.
Miriam Braga, Diletta Barbiani, Mehran Emadi Andani, Bernardo Villa-Sánchez, Michele Tinazzi, Mirta Fiorio   +5 more
doaj   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

EL PLACEBO: LUCES Y SOMBRAS Placebo: Lights and shadows

Revista Habanera de Ciencias Médicas, 2008
Se realiza una revisión sobre el placebo definiéndose su concepto, así como del efecto placebo, sus reacciones en el organismo, utilidad en las investigaciones, sus posibles usos en la práctica médica y los peligros de su empleo.
José Díaz Novás
doaj  

An educational placebo effect intervention reduces the likelihood of athletes using performance enhancing drugs [PDF]

, 2018
Background Recent research has reported that placebo effects can significantly improve sport performance. However, while research has generated knowledge about placebo effects on sport performance, there is limited research devoted to how this can ...
Beedie, C., Hurst, P., Coleman, D., Foad, A.   +3 more
core  

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Should we reconsider the routine use of placebo controls in clinical research?

Trials, 2012
Background Modern clinical-research practice favors placebo controls over usual-care controls whenever a credible placebo exists. An unrecognized consequence of this preference is that clinicians are more limited in their ability to provide the benefits ...
Avins Andrew L, Cherkin Daniel C, Sherman Karen J, Goldberg Harley, Pressman Alice   +4 more
doaj   +1 more source